These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 32828676)

  • 1. Clinical evaluation of cefotiam in the treatment of bacteremia caused by Escherichia coli, Klebsiella species, and Proteus mirabilis: A retrospective study.
    Hashiguchi Y; Oda K; Katanoda T; Nosaka K; Jono H; Saito H
    J Infect Chemother; 2020 Nov; 26(11):1158-1163. PubMed ID: 32828676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propensity score-matched analysis comparing the therapeutic efficacies of cefazolin and extended-spectrum cephalosporins as appropriate empirical therapy in adults with community-onset Escherichia coli, Klebsiella spp. and Proteus mirabilis bacteraemia.
    Hsieh CC; Lee CH; Hong MY; Hung YP; Lee NY; Ko WC; Lee CC
    Int J Antimicrob Agents; 2016 Dec; 48(6):712-718. PubMed ID: 27836382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Definitive Cefazolin Therapy for Stabilized Adults with Community-Onset
    Hsieh CC; Chen PL; Lee CH; Yang CY; Lee CC; Ko WC
    J Clin Med; 2020 Jan; 9(1):. PubMed ID: 31936020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensity-matched analysis of the impact of extended-spectrum β-lactamase production on adults with community-onset Escherichia coli, Klebsiella species, and Proteus mirabilis bacteremia.
    Lee CC; Lee CH; Hong MY; Hsieh CC; Tang HJ; Ko WC
    J Microbiol Immunol Infect; 2018 Aug; 51(4):519-526. PubMed ID: 28698042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical benefits of antimicrobial de-escalation in adults with community-onset monomicrobial Escherichia coli, Klebsiella species and Proteus mirabilis bacteremia.
    Lee CC; Wang JL; Lee CH; Hung YP; Hong MY; Tang HJ; Ko WC
    Int J Antimicrob Agents; 2017 Sep; 50(3):371-376. PubMed ID: 28694235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Definitive Cefazolin Treatment for Community-Onset Enterobacteriaceae Bacteremia Based on the Contemporary CLSI Breakpoint: Clinical Experience of a Medical Center in Southern Taiwan.
    Lee CC; Lee CH; Chen PL; Hsieh CC; Tang HJ; Ko WC
    Antibiotics (Basel); 2019 Nov; 8(4):. PubMed ID: 31717641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative activities of cefotiam and cefazolin against urinary tract infections with Proteus mirabilis in mice.
    Iwahi T; Tsuchiya K
    Antimicrob Agents Chemother; 1980 Aug; 18(2):257-63. PubMed ID: 7004338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral β-lactams vs fluoroquinolones and trimethoprim/sulfamethoxazole for step-down therapy for Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae bacteremia.
    McAlister MJ; Rose DT; Hudson FP; Padilla-Tolentino E; Jaso TC
    Am J Health Syst Pharm; 2023 Feb; 80(Suppl 1):S33-S41. PubMed ID: 35868628
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-Related Trends in Adults with Community-Onset Bacteremia.
    Lee CC; Wang JL; Lee CH; Hung YP; Hong MY; Chang CM; Ko WC
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Surveillance of susceptibility of clinical isolates to cefmetazole between 2000 and 2002].
    Abe T; Sato Y; Sei M
    Jpn J Antibiot; 2003 Dec; 56(6):574-83. PubMed ID: 15007873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Morphological studies on antibacterial activities of cefotiam (author's transl)].
    Konno M; Ubukata K; Takahashi H; Sawai M; Saito K
    Jpn J Antibiot; 1979 May; 32(5):583-97. PubMed ID: 379387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea.
    Ahn JY; Ann HW; Jeon Y; Ahn MY; Oh DH; Kim YC; Kim EJ; Song JE; Jung IY; Kim MH; Jeong W; Ku NS; Jeong SJ; Choi JY; Yong D; Song YG; Kim JM
    BMC Infect Dis; 2017 May; 17(1):327. PubMed ID: 28468622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microorganism Distributions and Antimicrobial Susceptibility in Community-Onset Bacteremia: A 6-Year Longitudinal Multicenter Cohort in Southern Taiwan.
    Huang YT; Yang CY; Hsieh CC; Hong MY; Lee CC
    J Acute Med; 2022 Mar; 12(1):13-22. PubMed ID: 35665314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of occurrence and antimicrobial susceptibility of Gram-negative bacteremia isolates in patients with urinary tract infection: results from United States and European hospitals (2009-2011).
    Sader HS; Flamm RK; Jones RN
    J Chemother; 2014 Jun; 26(3):133-8. PubMed ID: 24091000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from urinary tract infections (1989). I. Susceptibility distribution].
    Kumamoto Y; Hirose T; Tanaka N; Hikichi Y; Shigeta S; Shiraiwa Y; Kameoka H; Yoshida H; Ogata M; Tazaki H
    Jpn J Antibiot; 1995 Sep; 48(9):1131-60. PubMed ID: 7474333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Evaluation of the so-called basic cephalosporins using the serum bactericidal test].
    Milatovic D; Voss A; Machka K; Braveny I
    Med Klin (Munich); 1992 Feb; 87(2):58-62. PubMed ID: 1542283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Susceptibilities of uropathogenic bacteria to ampicillin, cefazolin, cefmetazole and gentamicin. Nine-year survey of changing patterns of susceptibilities].
    Igari J; Shitara M; Shitara M; Yoshimoto K; Hayashi Y
    Jpn J Antibiot; 1990 Sep; 43(9):1530-7. PubMed ID: 2262960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Analysis on distribution and drug resistance of pathogen caused community-onset bloodstream infection].
    Mao S; Ge Z; Zhao H; Cao J; Xia Z
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Jan; 31(1):67-72. PubMed ID: 30707872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Resistance spectrum of various bacteria against cefotiam in 3 Berlin clinics].
    Hahn H; Wagner J
    Immun Infekt; 1983 Jun; 11(4):140-2. PubMed ID: 6099820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.